Our pipeline, mainly focused on antibody-drug conjugates (ADCs), includes potential therapies that target specific molecules on cancer cells and modulate cancer cell function in ways that hold promise to improve human health.

Built by attaching a small molecule anticancer drug or another therapeutic agent to an antibody with a linker and, using the antibody's property to target a specific antigen only found on target cells, the ADCs deliver the highly potent drugs with a very high specificity to the cancer cells. They maximize the efficacy and minimize systemic exposure and their associated side effects.

Antibody Drug Conjugates – ADCs

TRL’s current programs utilize pyrrolobenzodiazepine (PBD)-based antibody drug conjugates (ADCs). TRL has multiple PBD-based ADCs in preclinical development and clinical trials.

Our lead program (MT-8633) is an anti-cMet ADC in a clinical trial for solid tumors. MT-8633 utilizes a humanized antibody specifically selected and engineered to be non-agonistic and efficiently deliver the toxic warhead to the DNA of tumor cells where it intercalates within the minor groove leading to disruption of replication, resulting in cell death.


MT-8633 (TR-1801-ADC) is an anti-cMet ADC comprising of a non-activating anti-Met antibody with a PBD toxin payload. It is currently in a Phase I dose escalation trial to evaluate safety, pharmacokinetics, and anti-tumor activity in patients with cMet+ solid tumors.


Interested in joining our team? We seek individuals who work with honesty and integrity; who are willing to push the boundaries and explore new ideas; who take ownership and thrive on accountability; and who perform their work with a sense of urgency, but also an optimistic and solution-oriented attitude.